Core Viewpoint - The unexpected tax payment of approximately 16.67 million yuan by Guizhou Baiqiang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shenqi Pharmaceutical, adds pressure to the company's growth and will directly impact its 2025 performance [2][5][11]. Financial Impact - The tax payment and late fees amount to 16.67 million yuan, which represents 33.12% of Shenqi Pharmaceutical's net profit of 50.3 million yuan for the first three quarters of 2025 [5][10]. - The company's revenue for the same period was 1.398 billion yuan, indicating that the tax payment significantly affects profitability [5]. Market Reaction - Despite the negative news, the market reacted relatively calmly, with Shenqi Pharmaceutical's stock price closing at 6.48 yuan, a slight increase of 1.25%, and a market capitalization of 3.46 billion yuan [4]. - On November 25, the stock price rose over 4%, influenced by movements in the flu sector [4]. Internal Control Issues - This incident is not the first time Shenqi Pharmaceutical has faced scrutiny over financial compliance, as it previously received regulatory warnings for fabricating consulting fees to misappropriate funds [6][7]. - The tax payment issue highlights potential weaknesses in the company's internal controls and financial oversight of its subsidiaries [11]. Industry Context - Shenqi Pharmaceutical operates in a challenging environment characterized by policy pressures such as volume-based procurement and medical insurance cost control, which affect the pharmaceutical industry as a whole [9]. - The company's high price-to-earnings ratio of 51.6 suggests that its stock price may have already priced in future growth expectations [8].

一、运营数据 1．主营业务分行业情况 单位：元 2．主营业务分类情况 单位：元 证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2025-037 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2025 年三季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | 营业收入 | | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | 分产品 | 营业收入 | 营业成本 | 毛利率 | 比上年同 | 营业成本 比上年同 | 比上年 同期增 | | | | | （%） | 期增减 | | | | | | | | （%） | 期增减（%） | 减百分 | | | | | | | | 点 | | 抗肿瘤药 系列 | 387,676,903.77 | 47,684,697.25 | 87.70 | -5.14 | 3.73 | -1.05 | | 皮肤外用抗菌 | 67,252,647.99 | 9, ...

Core Viewpoint - The company reported a significant decline in its main business revenue for the first half of 2025, with a total revenue of 960.85 million yuan, representing a decrease of 149.52 million yuan or 13.47% compared to the previous year [10][12]. Financial Data - The main business revenue for the reporting period was 960.85 million yuan, down from the previous year's figure [10]. - The pharmaceutical manufacturing segment saw a revenue decline of 119.97 million yuan, a decrease of 17.88% [10]. - The pharmaceutical commercial segment experienced a revenue drop of 29.55 million yuan, a decrease of 6.73% [10]. - The total sales revenue from major products was 523.22 million yuan, reflecting a decrease of 123.81 million yuan or 19.14% year-on-year [11]. Regional Performance - Sales revenue by region showed varied performance, with North China experiencing a slight increase of 4.32%, while other regions faced declines: South China down 35.01%, Southwest down 21.33%, Northwest down 20.25%, Northeast down 17.89%, Central China down 12.58%, and East China down 9.53% [12]. - Exports saw a dramatic decline of 88.15% compared to the same period last year [12]. Shareholder Activity - Zhang Ya, a significant shareholder, reduced her holdings by 10,304,700 shares, which accounted for 1.93% of the company's total share capital [3][4].